The next medical milestone may hit a wall. A new federal proposal intended to protect U.S. national security could have unintended consequences for patients waiting on the next generation of treatments. The Treasury Department wants to restrict certain American investments in biotechnology overseas, but its proposed definition is broad enough to include medicines, vaccines and promising new therapies. Patients Rising supports protecting American interests, but national security policies must be precise enough to avoid creating unnecessary barriers to medical innovation. Terry Wilcox, Chief Patient Advocate of Patients Rising, is calling on Treasury to reconsider how broadly the restrictions are written before the rule is finalized. Read more about what's at stake for patients and why Patients Rising is speaking out: